

Arkansas Blue Cross and Blue Shield FEP Drug List

The purpose of this document is to provide the location of the medical necessity criteria that Prime Therapeutics Management will require to render clinical determinations for the Medical Pharmacy Prior Approval program. Additional information can be obtained by visiting the FEP website. **Please note that both websites also contain links to policies that are not managed in the prior approval program administered by Prime Therapeutics Rx Management on behalf of Arkansas Blue Cross and Blue Shield FEP.**

HCPSC	Brand name	Generic name	Therapeutic class	Effective date PA	Policy	Criteria Location
Q2055	Abecma	Idecabtagene Vicleucel	CAR-T	1/1/2022	5.21.173	FEP
J9042	Adcetris	brentuximab vedotin	Oncology	3/1/2022	5.21.019	CVS
J9029	Adstiladrin	Nadofaragene	Gene Therapy	7/1/2023	5.21.205	FEP
Q5150	Ahzantive	AFLIBERCEPT-MRBB	Ophthalmic Injections	3/1/2022	5.90.026	CVS
J1552	Alyglo	immune globulin intravenous, human	Immune Globulin	3/1/2022	5.20.003	CVS
Q5126	Allymsys	bevacizumab-maly	Oncology	1/1/2024	5.21.004	CVS
C9399, J9999	Amtagvi	Lifileucel	CAR-T like	2/19/2024	5.21.219	FEP
J0225	Amvuttra	vutrisiran	transthyretin-directed small interfering RNA (siRNA)	1/1/2024	5.75.037	CVS
J0881	Aranesp (non-ESRD)	darbepoetin	Erythropoiesis-Stimulating Agents	3/1/2022	5.85.01	CVS
J1554	Asceniv	immune globulin intravenous, human – slra	Immune Globulin	3/1/2022	5.20.003	CVS
Q2058	Aucatzyl	Obecabtagene Autoleucel	Gene Therapy	11/8/2024	5.21.236	FEP
J9035	Avastin (oncology only)	bevacizumab	Oncology	3/1/2022	5.21.004	CVS
Q5121	Avsola	infliximab-axxq	BDAID	3/1/2022	5.50.002	CVS
J9999	Avzivi	Bevacizumab-tnjn	ONCOLOGY	1/1/2026	5.21.004	FEP
J0179	Beovu	brocuzumab-dbl	Ophthalmic Injections	3/1/2022	5.90.026	CVS
J1414	Beqvez	Fidanacogene Elaparvovec	Gene Therapy	10/1/2024	5.85.062	FEP
J1556	Bivigam	intravenous immune globulin	Immune Globulin	3/1/2022	5.20.003	CVS
Q5152	Bkemv	Eculizumab-aeeb	Hematology	1/1/2026	5.85.011	FEP
Q5158	Bomyntra	Denosumab-bnht	Oncology	1/1/2026	5.30.018	FEP
Q2054	Breyanzi	Lisocabtagene Maraleucel	CAR-T	1/1/2022	5.21.169	FEP
J2329	Briumvi	Ublituximab	Multiple Sclerosis	1/1/2026	5.60.057	CVS
Q5124	Byooviz	ranibizumab-nuna	Ophthalmic Injections	1/1/2024	5.90.029	CVS
Q2056	Carvykti	Ciltacabtagene Autoleucel	CAR-T	10/1/2022	5.21.188	CVS
J3392	Casgevvy	Exagamglogene autotemcel	Gene Therapy	12/8/2023	5.85.057	CVS
Q5128	Cimerli	ranibizumab-eqrn	Ophthalmic Injections	1/1/2024	5.90.029	CVS
Q5158	Conexence	Denosumab-bnht	Oncology	1/1/2026	5.30.017	CVS

HCPCS	Brand name	Generic name	Therapeutic class	Effective date PA	Policy	Criteria Location
J1551	Cutaquig	immune globulin subcutaneous (human) - hipp	Immune Globulin	3/1/2022	5.20.008	CVS
J1555	Cuvitru	subcutaneous immune globulin	Immune Globulin	3/1/2022	5.20.008	CVS
J9144	Darzalex Faspro	daratumumab; hyaluronidase-fihj	Oncology	3/1/2022	5.21.147	CVS
J7318	Durolane	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
J1413	Elevidys	Delandistrogene Moxeparvovec	Gene Therapy	8/22/2023	5.75.042	CVS
J3590	Encelto	Revakinagene Taroretcel	Gene Therapy	3/5/2025	5.90.074	CVS
J3403	Encelto	REVAKINAGENE TARORETCEL-LWEY	OPHTHALMIC INJECTIONS	1/1/2026	5.90.074	CVS
J9358	Enhertu	deruxtecan-nxki	Oncology	3/1/2022	5.21.138	CVS
Q5149	Enzeevu	AFLIBERCEPT-ABZV	Ophthalmic Injections	3/2/2022	5.90.026	CVS
Q5151	Epysqli	Ecuzumab-aagh	Hematology	1/1/2026	5.85.011	CVS
J7323	Euflexxa	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09	CVS
J0178	Eylea	aflibercept	Ophthalmic Injections	3/1/2022	5.90.026	CVS
J0177	Eylea HD	Ocular VEGF-aflibercept	Recombinant fusion protein	1/1/2026	5.90.026	CVS
J1572	Flebogamma	intravenous immune globulin	Immune Globulin	3/1/2022	5.20.003	CVS
Q5108	Fulphila	pegfilgrastim-jmdb	Colony-Stimulating Factors	3/1/2022	5.85.009	CVS
Q5130	Fynetra	pegfilgrastim-pbbk	Colony-Stimulating Factors	1/1/2026	5.85.009	CVS
J1560	GamaSTAN S/D	intravenous immune globulin	Immune Globulin	3/1/2022	5.20.003	CVS
J1569	Gammagard Liquid	intravenous immune globulin	Immune Globulin	3/1/2022	5.20.003	CVS
J1566	Gammagard S/D (powder)	immune globulin	Immune Globulin	3/1/2022	5.20.003	CVS
J1561	Gammaked	intravenous immune globulin	Immune Globulin	3/1/2022	5.20.003	CVS
J1557	Gammaplex	intravenous immune globulin	Immune Globulin	3/1/2022	5.20.003	CVS
J1561	Gamunex-C	intravenous immune globulin	Immune Globulin	3/1/2022	5.20.003	CVS
J7326	Gel-One	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
J7328	Gel-Syn	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
J7320	GenVisc 850	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
J0223	Givlaari	givosiran	Rare Disease	1/1/2023	5.85.037	CVS
J1447	Granix	tbo-filgrastim	Colony-Stimulating Factors	3/1/2022	5.85.010	CVS
J1411	Hemgenix	Etranacogene Dezaparvovec	Gene Therapy	4/1/2023	5.85.048	CVS
J9355	Herceptin	trastuzumab	Oncology	3/1/2022	5.21.126	CVS
J9356	Herceptin Hylecta	hyaluronidase-oysk/trastuzumab	Oncology	3/1/2022	5.21.126	CVS
Q5146	Hercessi	trastuzumab-strf	Oncology	3/1/2022	5.21.126	CVS
Q5113	Herzuma	trastuzumab-pkrb	Oncology	3/1/2022	5.21.126	CVS
J1559	Hizentra	injection, immune globulin	Immune Globulin	3/1/2022	5.20.008	CVS

HCPCS	Brand name	Generic name	Therapeutic class	Effective date PA	Policy	Criteria Location
J7321	Hyalgan	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
J7322	Hymovis	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
J1575	HyQvia	injection, immune globulin/ hyaluronidase	Immune Globulin	3/1/2022	5.20.008	CVS
J9256	Imaavy	Nipocalimab-aahu	MYASTHENIA GRAVIS	1/1/2026	5.85.066	CVS
J9325	Imlygic	Talimogene Laherparepvec	Gene Therapy	1/1/2022	5.50.002	CVS
Q5098	Imuldosa IV	USTEKINUMAB-SRLF	BDAID: Crohns Disease/ Ulcerative Colitis	1/1/2026	5.90.004	CVS
Q5103	Inflectra	infliximab-dyyb	Autoimmune	3/1/2022	5.50.002	CVS
Q5160	Jobevne	BEVACIZUMAB-NWGD	SPECIAL	1/1/2026	5.21.004	CVS
Q5136	Jubbonti	Denosumab-bbdz	Oncology	1/1/2026	5.30.017	CVS
J9354	Kadcyla	ado-trastuzumab emtansine	Oncology	3/1/2022	5.21.032	CVS
Q5117	Kanjinti	trastuzumab-anns	Oncology	3/1/2022	5.21.006	CVS
J3590	Kebilidi	Eladocagene Exuparvovec	Gene Therapy	11/13/2024	5.30.094	CVS
J9271	Keytruda	pembrolizumab	Oncology	3/1/2022	5.21.050	CVS
Q2042	Kymriah	Tisagenlecleucel	CAR-T	1/1/2022	5.21.101	CVS
C9399, J3590	Lantidra	Donislecel	Cellular therapy	10/1/2023	5.30.089	CVS
C9399, J3590	Lenmeldy	Atidarsagene Autotemcel	Gene Therapy	3/18/2024	5.85.058	CVS
J2778	Lucentis	ranizumab	Ophthalmic Injections	3/1/2022	5.90.029	CVS
J3398	Luxturna	voretigene	Ophthalmic Injections	3/1/2022	5.90.33	FEP
J3394	Lyfgenia	Lovotibeglogene autotemcel	Gene Therapy	7/1/2024	5.85.058	CVS
J7327	Monovisc	hyaluronic acid	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
Q5107	Mvasi	bevacizumab-awwb	Oncology	3/1/2022	5.21.004	CVS
J2506	Neulasta	pegfilgrastim	Colony-Stimulating Factors	3/1/2022	5.85.009	CVS
J1442	Neupogen	filgrastim	Colony-Stimulating Factors	3/1/2022	5.85.010	CVS
Q5110	Nivestym	filgrastim-aafi	Colony-Stimulating Factors	3/1/2022	5.85.010	CVS
Q5148	Nypozi	filgrastim-txid	Colony-Stimulating Factors	3/2/2022	5.85.011	CVS
Q5122	Nyvepria	pegfilgrastim-apgf	Colony-Stimulating Factors	3/1/2022	5.85.009	CVS
J2350	Ocrevus	ocrelizumab	Multiple Sclerosis	3/1/2022	5.60.28	CVS
J1568	Octagam	intravenous immune globulin	Immune Globulin	3/1/2022	5.20.003	CVS
Q5114	Ogivri	trastuzumab-dkst	Oncology	3/1/2022	5.21.032	CVS
J3590	Omisirge	omidubicel	Cellular therapy	4/18/2023	5.85.049	CVS
J0222	Onpattro	patisiran	Rare Disease	3/1/2022	5.75.23	FEP
Q5112	Ontruzant	trastuzumab-dttb	Oncology	3/1/2022	5.21.126	CVS

HCPCS	Brand name	Generic name	Therapeutic class	Effective date PA	Policy	Criteria Location
J9299	Opdivo	nivolumab	Oncology	3/1/2022	5.21.239	CVS
Q5153	Opuviz	aflibercept-yszy	Ophthalmic Injections	3/3/2022	5.90.026	CVS
J7324	Orthovisc	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
Q5157	Osenvelt	Denosumab-bmwo	Oncology	1/1/2026	5.30.018	CVS
Q5159	Ospomyv	Denosumab-dssb	Oncology	1/1/2026	5.30.017	CVS
Q9999	Otulf	Ustekinumab-aaaz	BDAID: Crohns Disease/ Ulcerative Colitis	1/1/2026	5.90.004	CVS
J0224	Oxlumo	lumasiran	Rare Disease	1/1/2023	5.55.002	CVS
J1599	Panzyga	intravenous immune globulin	Immune Globulin	3/1/2022	5.20.003	CVS
Q5147	Pavblu	AFLIBERCEPT-AYYH	Ophthalmic Injections	3/4/2022	5.90.026	CVS
J9306	Perjeta	pertuzumab	Oncology	3/1/2022	5.21.097	CVS
J1459	Privigen	intravenous immune globulin	Immune Globulin	3/1/2022	5.20.003	CVS
J0885	Procrit/Epogen (non ESRD)	epoetin alfa	Erythropoiesis-Stimulating Agents	3/1/2022	5.85.06	CVS
J0897	Prolia	denosumab	Oncology	3/1/2022	5.30.017	CVS
Q2043	Provenge	sipuleucel-t	Oncology	3/1/2022	5.21.009	CVS
Q9997	Pyzchiva	Ustekinumab-ttwe	BDAID: Crohns Disease/ Ulcerative Colitis	1/1/2026	5.90.004	CVS
Q5125	Releuko	filgrastim-ayow	Colony-Stimulating Factors	1/1/2024	5.85.010	CVS
J1745	Remicade	infliximab	Autoimmune	3/1/2022	5.50.002	CVS
Q5104	Renflexis	infliximab-abda	Autoimmune	3/1/2022	5.50.002	CVS
Q5106	Retacrit	epoetin alfa-epbx	Erythropoiesis-Stimulating Agents	3/1/2022	5.85.06	CVS
C9399, J3590	Rethymic	allogeneic processed thymus tissue	Cellular therapy	1/1/2022	5.85.044	CVS
Q5123	Riabni	rituximab-arrx	Oncology	1/1/2024	5.21.010	CVS
J9312	Rituxan	rituximab	Oncology	3/1/2022	5.21.096	CVS
J9311	Rituxan Hycela	rituxumab hyaluronidase	Oncology	3/1/2022	5.21.096	CVS
J1412	Roctavian	valoctocogene roxaparvovec	Gene Therapy	1/1/2024	5.85.051	CVS
J1449	Rolvedon	eflapegrastim-xnst	Colony-Stimulating Factors	1/1/2024	5.85.047	CVS
Q5119	Ruxience	rituximab-pvvr	Oncology	3/1/2022	5.21.096	CVS
J9333	Rystiggo	rozanolixizumab-noli	CURRENTLY UNCLASSIFIED	1/1/2026	5.85.050	FEP
Q9998	Selarsdi	Ustekinumab-aekn	BDAID: Crohns Disease/ Ulcerative Colitis	1/1/2026	5.90.004	CVS
J1602	Simponi Aria	golimumab	BDAID	3/1/2022	5.70.51	CVS

HCPCS	Brand name	Generic name	Therapeutic class	Effective date PA	Policy	Criteria Location
J2327	Skyrizi IV	risankizumab-rzaa	Autoimmune	10/1/2023	5.90.038	CVS
C9399, J3590	Skysona	elivaldogene autotemcel	Gene Therapy	9/16/2022	5.60.055	CVS
J1299	Soliris	eculizumab	Hematology	3/1/2022	5.85.11	CVS
J2326	Spinraza	nusinersen	CNS Agents: Rare Diseases	3/1/2022	5.75.15	FEP
J3358	Stelara IV	ustekinumab	BDAID: Crohns Disease/ Ulcerative Colitis	3/1/2022	5.90.04	CVS
J3357	Stelara SQ	Ustekinumab SQ	BDAID: Crohns Disease/ Ulcerative Colitis	1/1/2024	5.90.004	CVS
Q5099	Steqeyma IV	ustekinumab-stba	BDAID: Crohns Disease/ Ulcerative Colitis	1/1/2026	5.90.005	CVS
Q5127	Stimufend	pegfilgrastim-fpgk	Colony-Stimulating Factors	3/1/2022	5.85.009	CVS
Q5157	Stoboclo	Denosumab-bmwo	Oncology	1/1/2026	5.30.018	CVS
J7321	Supartz FX	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
J7331	Synojoint	sodium hyaluronate	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
J7325	Synvisc	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
J7325	Synvisc One	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
Q2053	Tecartus	brexucabtagene autoleucel	CAR-T	1/1/2022	5.21.155	CVS
C9399, J9999	Tecelra	afamitresgene autoleucel	CAR-T like	8/2/2024	5.21.225	CVS
J3490	Tegsedi	inotersen	TRR Amyloidosis	1/1/2023	5.75.025	CVS
J3241	Tepezza	teprotumumab	Thyroid Eye Disease	1/1/2026	5.30.064	CVS
Q5116	Trazimera	trastuzumab-qyyp	Oncology	3/1/2022	5.21.126	CVS
J7332	Triluron	sodium hyaluronate	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
J7329	Trivisc	sodium hyaluronate	Hyaluronic Acid Derivatives	1/1/2026	5.75.009	CVS
Q5115	Truxima	rituxumab-abbs	Oncology	3/1/2022	5.21.096	CVS
Q5134	Tyruko	natalizumab-sztn	Multiple Sclerosis	1/1/2026	5.60.13	CVS
J2323	Tysabri	natalizumab	Multiple Sclerosis	3/1/2022	5.60.13	CVS
Q5111	Udenyca	pegfilgrastim-cbqv	Colony-Stimulating Factors	3/1/2022	5.85.009	CVS
J1303	Ultomiris	ravulizumab-cwvz	Rare Disease	3/1/2022	5.85.33	CVS
J2777	Vabysmo	faricimab-svoa	Ophthalmic Injections	1/1/2024	5.90.026	CVS
Q5129	Vegzelma	bevacizumab-adcd	Oncology	1/1/2024	5.21.004	CVS
J7321	Visco-3	hyaluronan or derivative	Viscosupplementation	3/1/2022	5.75.09,2.01.21	CVS
J3401	Vyjuvek	beremagene geperpavec	Gene Therapy	1/1/2024	5.90.063	CVS

HCPCS	Brand name	Generic name	Therapeutic class	Effective date PA	Policy	Criteria Location
J9332	Vyvgart	efgartigimod alfa-fcab	Neurologic Disorders	1/1/2023	5.99.026	FEP
J9334	Vyvgart Hytrulo	efgartigimod alfa and hyaluronidase-qvfc	Neurologic Disorders	1/1/2024	5.99.026	FEP
Q5138	Wezlana IV	Ustekinumab-auub	BDAID: Crohns Disease/ Ulcerative Colitis	1/1/2026	5.90.004	CVS
Q5137	Wezlana SQ	Ustekinumab-auub	BDAID: Crohns Disease/ Ulcerative Colitis	1/1/2026	5.90.004	CVS
Q5136	Wyost	Denosumab-bbdz	Oncology	1/1/2026	5.30.017	CVS
Q5159	Xbryk	Denosumab-dssb	Oncology	1/1/2026	5.30.017	CVS
J1558	Xembify	immune globulin human - klhw	Immune Globulin	3/1/2022	5.20.008	CVS
J0897	Xgeva	denosumab	Oncology	3/1/2022	5.30.018	CVS
Q5155	Yesafili	AFLIBERCEPT-JBVF	Ophthalmic Injections	3/5/2022	5.90.026	CVS
Q2041	Yescarta	axicabtagene ciloleucel	CAR-T	1/1/2022	5.21.105	CVS
Q5100	Yesintek	Ustekinumab-kfce	BDAID: Crohns Disease/ Ulcerative Colitis	1/1/2026	5.90.004	CVS
Q5101	Zarxio	filgrastim-sndz	Colony-Stimulating Factors	3/1/2022	5.85.010	CVS
J3389	Zevaskyn	Prademagene Zamkikeracel	RARE DISEASE	01/01/026	5.90.075	CVS
Q5120	Ziextenzo	pegfilgrastim-bmez	Colony-Stimulating Factors	3/1/2022	5.85.009	CVS
Q5118	Zirabev	bevacizumab-bvzr	Oncology	3/1/2022	5.21.004	CVS
J3399	Zolgensma	onasemnogene abeparvovec	Rare Disease	3/1/2022	5.75.27	FEP
J1748	Zymfentra SQ	Infliximab-dyyb	BDAID	1/1/2026	5.50.002	CVS
J3393	Zynteglo	betibeglogene autotemcel	Gene Therapy	7/1/2024	5.99.029	FEP

Other drugs may require prior approval through Arkansas Blue Cross and Blue Shield, and the above list subject to change.

To view additional resources, please visit arkansasbluecross.com/providers/resource-center/specialty-pharmacy.

00342.05.01-v010526-1051